Mount Sinai Research Challenges Longstanding Assumptions on mRNA Vaccine Immunity Mechanisms

The Breakthrough from Mount Sinai's Icahn School of Medicine

Researchers at the Icahn School of Medicine at Mount Sinai have uncovered groundbreaking insights into how messenger RNA (mRNA) vaccines trigger immunity, upending a core belief in vaccine science. Traditionally, scientists assumed that the key to robust protection lay in mRNA directly transfecting professional antigen-presenting cells, like dendritic cells, at the injection site to kickstart the immune response. This new study, published in Nature Biotechnology on April 29, 2026, demonstrates that this isn't the case. Instead, antigen produced by non-immune cells is efficiently cross-presented to T cells by dendritic cells, while liver cells—known as hepatocytes—actually hinder the process. This discovery not only reframes our understanding of mRNA vaccine mechanisms but also paves the way for more potent formulations, particularly for challenging targets like cancer.

The work stems from the Precision Immunology Institute at Mount Sinai, highlighting how U.S. medical schools continue to lead in translational research. Led by MD/PhD student Sophia Siu in Brian D. Brown's lab, with collaborators including Miriam Merad, the team engineered mRNA with microRNA target sites (miRTs) to selectively silence expression in specific cell types. This allowed precise testing of each cell's contribution to immunity.

Understanding mRNA Vaccines: From COVID-19 to Beyond

mRNA vaccines represent a revolutionary platform where synthetic messenger RNA, encased in lipid nanoparticles (LNPs), instructs cells to produce a target protein—such as the SARS-CoV-2 spike protein—mimicking a viral infection. This protein is then processed and displayed on the cell surface via major histocompatibility complex (MHC) molecules, alerting CD8 cytotoxic T cells and CD4 helper T cells to mount a defense. The platform's speed and adaptability propelled its success during the pandemic, with boosters eliciting strong antibody and T cell responses.

However, LNPs don't discriminate; they transfect a mix of cells including muscle fibers at intramuscular injection sites, liver hepatocytes after systemic spread, and rare immune cells. Questions lingered: Which cells drive the observed immunity? Mount Sinai's study provides clarity, showing the liver's unexpected role as a suppressor and muscle as an enhancer.

Challenging the Dendritic Cell-Centric View

For decades, immunologists believed dendritic cells (DCs)—the most efficient antigen-presenting cells—must be directly transfected by mRNA for optimal T cell activation. This view stemmed from DC vaccines in cancer trials, where loading DCs ex vivo with antigen showed promise but limited scalability.

Mount Sinai tested this by incorporating miR-142 target sites into mRNA, silencing expression in hematopoietic cells (including DCs). Remarkably, T cell responses and antibody production remained intact, matching wild-type mRNA. DCs acquired antigen from transfected non-immune cells via cross-presentation—endocytosing apoptotic bodies, extracellular vesicles, or free protein—and presented it effectively. This mechanism, long known for viral infections, proves dominant for mRNA vaccines, freeing designers from DC-targeting constraints.

Hepatocytes: Unexpected Suppressors of Immunity

The liver emerged as the villain. Intravenous LNPs heavily transfect hepatocytes, which express the antigen but dampen responses through programmed death-1 (PD-1)/PD-L1 signaling, inducing T cell exhaustion. By adding miR-122 targets (abundant in liver), the team silenced hepatocyte expression, tripling antigen-specific CD8 T cells, boosting effector functions like interferon-gamma and granzyme B, and slashing exhaustion markers.

"We found that hepatocytes actively dampen the immune response to mRNA vaccines," Siu explained. Anti-PD-1 therapy reversed this suppression, confirming the pathway. In repeated dosing, detargeting also curbed liver inflammation and enzyme leaks, improving safety.

Muscle Cells: Boosters Through Cross-Presentation

Intramuscular injections favor myocytes. Silencing via miR-133/206 targets reduced T cell priming by 30-50%, revealing muscle's supportive role. Myocytes upregulate MHC class I upon transfection, releasing antigen for DC uptake. This cross-priming pathway explains mRNA vaccines' potency despite low DC transfection rates (often <1%).

The study used reporter genes like GFP and OVA antigen in mouse models, tracking responses with tetramers and flow cytometry. Muscle-derived antigen fueled superior CD8 activation compared to liver sources.

Photo by Diana Polekhina on Unsplash

Proof in Lymphoma: Real-World Therapeutic Impact

To test clinical relevance, researchers challenged mice with A20 lymphoma expressing GFP antigen. Wild-type mRNA vaccines slowed growth, but hepatocyte-detargeted versions (miR-122T) slashed tumor burden over 50%, with more activated, less exhausted tumor-infiltrating T cells. Splenic responses amplified, prolonging survival.

This mirrors adoptive T cell therapies (like Jedi TCR-transgenic cells), where detargeting minimized liver toxicity while maximizing expansion. For CAR-T augmentation, it preserved efficacy sans hepatotoxicity—a boon for mRNA-encoded bispecifics or cytokines.

Read the full study for detailed lymphoma data: Nature Biotechnology paper.

Innovative miRT Technology: A Versatile Tool

The miRT system—short synthetic sequences in the mRNA's 3' untranslated region (UTR)—binds cell-specific miRNAs, recruiting degradation machinery without toxicity. Proven across antigens (OVA, SARS-CoV-2 Spike, GFP), routes (i.m./i.v.), and nucleoside modifications, it's modular for custom detargeting.

Mount Sinai's approach builds on SORT nanoparticles but uses genetic silencing for precision. Future iterations could combine with liver-avoiding LNPs, amplifying gains.

Implications for Cancer Vaccines and Beyond

Cancer mRNA vaccines (e.g., Moderna's mRNA-4157) struggle with weak immunogenicity against self-like neoantigens. Hepatocyte detargeting could supercharge Tfh cells, germinal centers, and memory B cells, vital for durable protection. In infectious diseases, it counters variants by broadening T cell repertoires.

Beyond vaccines, miRTs enable tissue-specific gene therapies, reducing off-target effects in liver-heavy AAV/mRNA delivery. Mount Sinai's press release details broader applications: Mount Sinai announcement.

Mount Sinai's Leadership in Vaccine Research

The Icahn School exemplifies U.S. higher education's biotech prowess. Home to the Tisch Cancer Institute and Genomics Institute, it fosters MD/PhD programs training leaders like Siu. Collaborations with industry (e.g., BioNTech alumni) accelerate translation, yielding spinouts like Kantaro for serology.

This work underscores med schools' role in post-COVID innovation, securing NIH grants amid funding debates. U.S. universities produce 40% of global mRNA papers, driving economic impact via patents and startups.

Career Opportunities in mRNA Research at U.S. Universities

Such discoveries spotlight demand for immunologists, bioengineers, and virologists. Mount Sinai and peers like UPenn, Harvard seek faculty for RNA therapeutics. Postdocs in nanoparticle design or T cell engineering abound, with salaries averaging $70K-$90K starting.

Higher ed's interdisciplinary hubs—e.g., Mount Sinai's Precision Immunology—offer tenure tracks blending basic science and trials, amid booming biotech hiring (20% rise projected 2026).

Photo by Mufid Majnun on Unsplash

Future Directions and Challenges Ahead

Human trials loom: miRT-mRNA for melanoma or lymphoma boosters? Challenges include LNP optimization for humans (higher liver uptake) and scaling miRTs for multi-antigen cocktails. Regulatory nods for detargeted platforms could redefine vaccines by 2030.

U.S. universities must navigate funding cuts, but NIH's ARPA-H prioritizes RNA tech. Mount Sinai's pipeline—from pan-coronavirus to antibiotic mRNA—positions academia as innovation vanguard.

This research exemplifies how med schools drive public health, training the next generation amid evolving threats like antimicrobial resistance and cancer surges.